News | Cardiovascular Education | April 25, 2024

Heart-Valve-Surgery.Com, Medtronic Launch Novel 'Aortic Stenosis Patient Activation Platform' to Empower Patients

Aortic Stenosis Patient Activation Platform

April 25, 2024 —Heart-Valve-Surgery.com, a leading patient advocacy group for heart valve disease, with support from Medtronic, a global leader in healthcare technology, launched the "Aortic Stenosis Patient Activation Platform", an end-to-end digital platform for patient awareness, patient education, and patient activation specific to aortic valve stenosis.

Aortic stenosis is a narrowing of the aortic valve which prevents the aortic leaflets from opening and closing properly.  As a result, the heart must work "over time" to pump blood throughout the body. Patients with aortic stenosis often have heart murmurs and experience debilitating symptoms including chest pain, dizziness, fatigue, shortness of breath and an irregular heartbeat. 

"Aortic stenosis is a deadly and under-treated disease," states Dr. Ashish Aneja, Director of Non-Invasive Cardiology at MetroHealth. Without treatment, up to 50% of patients will die 24 months after the onset of symptoms1. According to Dr. Kendra Grubb, Surgical Director of the Emory Structural Heart & Valve Center, approximately 40%† of patients with aortic stenosis in the United States do not get treatment because their symptoms are often misdiagnosed or ignored2.

Two common approaches for treating aortic stenosis include surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR). During the past 10 years, there has been a significant increase in the use of TAVR for aortic stenosis as the estimated number of TAVR procedures performed per year in the United States has increased from 4,600 procedures in 2012 to over 100,000 procedures in 20233.

Because treatment continues to increase and evolve, the "Aortic Stenosis Patient Activation Platform", developed by Heart-Valve-Surgery.com with support from Medtronic and a world-renowned team of physicians, will increase awareness and education for aortic stenosis patients. The proprietary platform leverages artificial intelligence, patient-centric algorithms, geolocation strategies, next-generation telephony engines, robust patient databases, and a social media following of over 500,000 people.  

"Using an integrated system of proprietary digital building blocks, the Aortic Stenosis Patient Activation Platform helps patients establish real-time connections with fifty heart teams that specialize in aortic stenosis treatment," states Adam Pick, who started Heart-Valve-Surgery.com after having an aortic valve replacement in 2006.

"At Medtronic, we are committed to helping aortic stenosis patients benefit from durable, minimally invasive devices that consider the lifetime management of heart valve disease," stated Nina Goodheart, Senior Vice President and President, Structural Heart & Aortic, which is part of the Cardiovascular Portfolio at Medtronic. "We appreciate the opportunity to partner with Heart-Valve-Surgery.com and heart teams across the nation on this important initiative."

To experience the Aortic Stenosis Patient Activation Platform, please click here.

To explore the TAVR Heart Team Finder, please click here. 

To download the new eBook, "Medtronic TAVR Procedure: What 7 Facts Should Patients Know?", click here.

For more information: https://www.heart-valve-surgery.com/


Related Content

News | Heart Failure

April 30, 2024 — A multicenter study led by Vanderbilt University Medical Center (VUMC) and Lipscomb University College ...

Home April 30, 2024
Home
News | Heart Failure

April 16, 2024 — Each year more than 500,000 Americans undergo percutaneous coronary intervention, or PCI, a minimally ...

Home April 16, 2024
Home
News | Heart Failure

April 12, 2024 — University of Virginia School of Medicine researchers have discovered a gene on the Y chromosome that ...

Home April 12, 2024
Home
News | Heart Failure

April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heart failure compared with those ...

Home April 02, 2024
Home
News | Heart Failure

March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American ...

Home March 29, 2024
Home
News | Heart Failure

March 25, 2024 — A team of engineers led by the University of Massachusetts Amherst and including colleagues from the ...

Home March 25, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions ...

Home March 15, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc., a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 15, 2024
Home
News | Heart Failure

March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2024
Home
News | Heart Failure

March 8, 2024 — The Texas Heart Institute, Georgia Institute of Technology (Georgia Tech), North Carolina State ...

Home March 08, 2024
Home
Subscribe Now